

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10524302	
	Filing Date		2005-11-21	
	First Named Inventor	Stephan Schwes		
	Art Unit	1631		
	Examiner Name	Mary K. Zeman		
	Attorney Docket Number	2002P56022WOUS		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524302
Filing Date	2005-11-21
First Named Inventor	Stephan Schwes
Art Unit	1631
Examiner Name	Mary K. Zeman
Attorney Docket Number	2002P56022WOUS

1	Brunham et al., Intestinal ABCA1 directly contributes to HDL biogenesis in vivo; J. of Clin. Investigation, 116(4): 1052-1062, (2006)	<input type="checkbox"/>
2	Yamada et al., Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals; Int. J. of Mol. Med., 21: 83-89, (2008)	<input type="checkbox"/>
3	Kyriakou et al., Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients; Human Mol. Genetics, 16(12): 1412-1422, (2007)	<input type="checkbox"/>
4	Tregouet et al., In-Depth Haplotype Analysis of ABCA1 Gene Polymorphisms in Relation to Plasma ApoA1 Levels and Myocardial Infarction; Arteriosclerosis, Thrombosis, and Vascular Biology, 24: 775-781 (2004)	<input type="checkbox"/>
5	Frikke-Schmidt et al., Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population; Arteriosclerosis, Thrombosis, and Vascular Biology, 28: 180-186 (2007)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.